Biotech entity
Financial Times is most often covered alongside AstraZeneca, which appears in 2 of these 2 stories. The clearest coverage concentration is acquisition: 1 of 2 stories, with the rest divided among 1 other category. The tracked stories average 3 original sources each.
Last mentioned: 4d ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Financial Times is most often covered alongside AstraZeneca, which appears in 2 of these 2 stories. The clearest coverage concentration is acquisition: 1 of 2 stories, with the rest divided among 1 other category. The tracked stories average 3 original sources each. This profile follows 2 Biotech stories mentioning Financial Times across the period from August 2, 2026 to August 3, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 12 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Financial Times. Shared-story counts are live from our verified record — not editorial picks.
The potential merger could dramatically reshape oncology and cardiovascular R&D pipelines, triggering a wave of consolidation among biotech firms seeking scale to compete with the new behemoth.
Source: eadt.co.uk · chardandilminsternews.co.uk
The merger would unite two cancer powerhouses, combining blockbusters like Opdivo and Tagrisso into a pipeline with more than 100 clinical programs. Biotech investors see a fusion of immuno-oncology and targeted therapy leadership.
Source: CNBC · finance.yahoo.com
Financial Times is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
